This article is more than 5 years old. Information may no longer be current.
FDA approves ‘ready-to-drink’ colonoscopy prep
Click Here to Manage Email Alerts
Ferring Pharmaceuticals announced the FDA approved its “ready-to-drink” low-volume colonoscopy prep, Clenpiq.
The prescription oral solution is a cranberry-flavored combination of the stimulant laxative sodium picosulfate, and magnesium oxide and anhydrous citric acid, which forms the osmotic laxative magnesium citrate, according to a press release. The product is indicated for adults undergoing colonoscopy, and the company expects it to be available in the first quarter of 2018.
“Successful bowel prep is critical for gastroenterologists to clearly see the inside of the colon during a colonoscopy,” Edward Brettholz, MD, clinical assistant professor of medicine at NYU School of Medicine, said in the press release. “The sheer volume of a prescribed bowel prep solution can be a barrier for some patients to adequately complete their prep regimen, leading to suboptimal visualization of the colon. Having a ready-to-drink, low volume colonoscopy prep in a pre-mixed oral solution is an excellent start to prepare patients for this important procedure to help detect and prevent colorectal cancer.”
“We expect that a ready-to-drink bowel preparation will aid physicians in their efforts to encourage colonoscopies among a patient population for whom various public health initiatives have called for increased screening,” Paul Navarre, CEO, Ferring Holding Inc., said in the press release.
Disclosures: Navarre is employed by Ferring. Healio Gastroenterology and Liver Disease was unable to confirm Brettholz’s relevant financial disclosures at the time of publication.
Collapse
Read more about
Click Here to Manage Email Alerts